40 employees
Bioceros provides services related to the preclinical development of monoclonal antibodies and generation protein-producing cell lines.
2003
Bioceros raised undisclosed on January 3, 2008
Investors: Thuja Capital
Bioceros raised undisclosed on September 16, 2005
Investors: Forbion